Get the Stockscreener App
8.21
2.61%
-0.22
After Hours:
8.21
Prothena Corporation Plc stock is traded at $8.21, with a volume of 551.06K.
It is down -2.61% in the last 24 hours and up +8.89% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$8.43
Open:
$8.43
24h Volume:
551.06K
Relative Volume:
0.47
Market Cap:
$441.94M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.21
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
-3.98%
1M Performance:
+8.89%
6M Performance:
-40.76%
1Y Performance:
-60.38%
1-Day Range:
$8.20
$8.49
1-Week Range:
$8.10
$8.62
52-Week Range:
$4.32
$22.71
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
8.21 | 447.06M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Applying Wyckoff theory to Prothena Corporation plc stockFed Meeting & Advanced Technical Analysis Signals - Newser
What moving averages say about Prothena Corporation plcJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Can volume confirm reversal in Prothena Corporation plcEarnings Growth Summary & AI Driven Stock Movement Reports - Newser
Using data tools to time your Prothena Corporation plc exitMarket Rally & Growth Oriented Trade Recommendations - Newser
Short interest data insights for Prothena Corporation plcWatch List & Growth Focused Entry Point Reports - Newser
Visual trend scoring systems applied to Prothena Corporation plcWeekly Market Outlook & Fast Exit and Entry Trade Guides - Newser
Institutional scanner results for Prothena Corporation plcJuly 2025 Intraday Action & Community Trade Idea Sharing - Newser
Has Prothena Corporation plc formed a bullish divergenceMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
Using fundamentals and technicals on Prothena Corporation plcWeekly Profit Recap & Fast Entry Momentum Trade Alerts - Newser
Can swing trading help recover from Prothena Corporation plc lossesJuly 2025 Trade Ideas & Daily Market Momentum Tracking - Newser
Prothena Down 40% Year to Date: What Lies Ahead for the Stock? - Yahoo Finance
Analysts Set Prothena Corporation plc (NASDAQ:PRTA) Target Price at $19.75 - Defense World
Relative strength of Prothena Corporation plc in sector analysisQuarterly Portfolio Report & Real-Time Market Sentiment Reports - Newser
Automated trading signals detected on Prothena Corporation plcJuly 2025 Sentiment & Accurate Buy Signal Notifications - Newser
Will Prothena Corporation plc price bounce be sustainableMarket Movement Recap & Consistent Profit Trading Strategies - Newser
Published on: 2025-09-10 05:55:27 - Newser
Strategies to average down on Prothena Corporation plc2025 Big Picture & Free High Return Stock Watch Alerts - Newser
What to do if you’re stuck in Prothena Corporation plcTrade Volume Report & Safe Entry Zone Identification - Newser
Chart overlay techniques for tracking Prothena Corporation plcEarnings Growth Report & High Return Stock Watch Alerts - Newser
What technical models suggest about Prothena Corporation plc’s comebackJuly 2025 Pullbacks & Entry Point Strategy Guides - Newser
Using data models to predict Prothena Corporation plc stock movementWeekly Stock Recap & Accurate Buy Signal Alerts - Newser
Is Prothena Corporation plc still worth holding after the dip2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Is Prothena Corporation plc showing insider buyingPortfolio Profit Report & AI Driven Stock Movement Reports - Lancaster City Council
Multi factor analysis applied to Prothena Corporation plcTrade Signal Summary & Daily Profit Focused Stock Screening - Newser
Prothena Corporation plc Shows Support at Fibonacci LevelNew Guidance & Weekly Watchlist of Top Performers - beatles.ru
Prothena Corporation plc $PRTA Stock Holdings Cut by Rafferty Asset Management LLC - MarketBeat
JMP Securities Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock Price - MarketBeat
What high frequency data says about Prothena Corporation plcMarket Weekly Review & Accurate Technical Buy Alerts - Newser
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):